English

Skandigen Interim report January - September 1996

Report this content

Skandigen Interim report January - September 1996 - The Group's sales amounted to MSEK 13.3 (11.0) for the period. The consolidated result after depreciation was MSEK -5.3 (-9.2). The result after net financial items amounted to MSEK 5.8 (-9.5). The net financial items include a non-recurring revenue from sale of subscription warrants of MSEK 10.2 (0). - The subsidiary Fermentech Medical Ltd. got approval in October to start clinical trials of its hyaluronan product for treatment of osteoarthritis. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net